Oncotelic Therapeutics Inc · OTC:OTLC
Oncotelic Therapeutics — Mateon Therapeutics — Corporate Update (February 2021)
11 slides from Oncotelic Therapeutics's corporate update, Feb 18, 2021
Slide 1: PulmoHeal & COVID-19: Ayurveda, Modern Biotech and AI to Address the COVID Pandemic in India
>| windlas + MATEQN THERAPEUTICS PulmoHeal™ 8& COVID-19 Ayurveda, Modern Biotech and Ah to Address the COVID Pandemic in India VUONG TRIEU N ww Feb 17, 2021 Windlas Healthcare (P) Limited Mateon Oncotelic Therapeutics Plot No. 183 & 192, Mohabewala Industrial Area, 29397 Agoura Rd Ste 107 Dehradun,
Slide 2: PulmoHeal Market Analysis
PulmoHeal Ma Analysis ( « PulmoHeal is positioned to capture two segments of respiratory health market on launch 1) Respiratory Viral Infection: The Global OTC Cold & Flu Drugs market is expected to reach $26.4 billion by 2027, growing at a CAGR of 8.4%. 2) Idiopathic Pulmonary Fibrosis : Idiopathic
Slide 3: 2X Faster Recovery From Respiratory Viral Infection
2X Faster Recovery From Respiratory Viral Infection Log-rank P-value = 0.004 = SOC+ PulmoHeal (N=18) Recovery (%) windlas _ Capsules —PulmoHeal Time (Days) Artemisia Annua Extract Capsule | rumor sienna ramacepoda tae and Riss Feteecth iieirintina sity + Vuong Trieu, Saran Saund, Prashant V. Rahate,
Slide 4: Supporting Publications
Supporting Publications medRyxiv @E_ BM) vale (se ‘THE PREPRINT SERVER FOR HEALTH SCIENCES 5 an # frontiers Experimental Pharmacology. and: Drtig, in Pharmacology Discovery i (OComment on this paper Raster Sle ese ari nt BEE ARTIVeda/PulmoHeal Accolerates Recovery from Mild-Moderate COVID-19 ‘Tubs A
Slide 5: AI Respiratory Health Assessment
ate Al Respiratory Health Assessment PulmoHeal Benefits Respiratory Assessme Hay Fever: Inflammation | Cough Pattern Normal or Restrictive or Obstructive Respiratory Viruses: Viral Replication) . Risk Yes or No COPD: Inflammation/Oxidation / v Severity Low/ Medium/ High CGHIGEE eeiding ” Dry Cough C
Slide 6: Supporting Publications
Supporting Publications Pharmacological Research Volurne 158, August 2020, 104901 Review Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases Derathy H.J. Cheong, Daniel W.S. Tan ®, Fred W.S. Wong! 4, Thai Tran 22.52 Show more + Addto Mendeley a2 Share 35 Cit
Slide 7: Phase IV PMS Platform
Phase IV PMS Platform Potential Indications Survey Informations Allergic Rhinitis: Hay Fever/ 600M pts As specified in potential Indications eee . . indications Respiratory Viruses: Common Cold & Flu/5-20% world . population Cough assessment Severity and type of cough Si ity and t f COPD: Chronic ob
Slide 8: Supporting Publications
Supporting Publications Cambridge Core Browse subjects The Global Impact of Respiratory Disease — Second Edition Home > Journals INFECTION Forum of International Respiratory Societies Epidemiology & Infection United for Lung Heattn Article contents Abstract Introduction Methods windlas + MATEON THER
Slide 9: Influenza Is Deadly Around the World
Influenza Is Deadly Around the World + Map of influenza fatality rate across the globe. Each country is coded to show how many people die every year from flu-related illness per 100,000 in population count. + https://championtraveler.com /news/the-us-flu-season-is- bad-this-year-but-influenza- is-st
Slide 10: Vaccine vs. Therapeutics
Vaccine vs. Therapeutics * COVID-19 is slated to become endemic with vaccine escape mutations arising from all regions * Vaccine will need redesign possibly annually * Therapeutics are need to treat infected patients Bos zoe eu) r windlas + MATEON THERAPEUTICS
Slide 11: Overall Strategy
Overall Strategy 1) Rapid Deployment of the Product to address emerging and/or new Indications nraeestiiuc 2) Crowd sourcing/ Democratizing Drug Development windlas + MATEON THERAPEUTICS
Mateon Therapeutics — Corporate Update (February 2021) on 6ix